DBV Technologies SA (DBVT) Receives Consensus Recommendation of “Buy” from Analysts
Shares of DBV Technologies SA (NASDAQ:DBVT) have been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the stock. One analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $50.00.
Several equities analysts recently issued reports on DBVT shares. Leerink Swann restated a “buy” rating and set a $54.00 price objective on shares of DBV Technologies SA in a research note on Tuesday, August 23rd. JMP Securities started coverage on DBV Technologies SA in a research note on Monday, September 26th. They set an “outperform” rating and a $47.00 price objective on the stock. Finally, Zacks Investment Research cut DBV Technologies SA from a “hold” rating to a “sell” rating in a research note on Tuesday, September 27th.
DBV Technologies SA (NASDAQ:DBVT) traded up 2.39% during trading on Tuesday, hitting $36.38. 37,546 shares of the stock were exchanged. The company’s market cap is $1.67 billion. DBV Technologies SA has a one year low of $22.55 and a one year high of $37.98. The stock’s 50 day moving average is $36.04 and its 200-day moving average is $33.79.
Large investors have recently bought and sold shares of the stock. Alliancebernstein L.P. boosted its stake in DBV Technologies SA by 20.3% in the second quarter. Alliancebernstein L.P. now owns 794,220 shares of the company’s stock worth $25,907,000 after buying an additional 133,953 shares during the last quarter. BlackRock Institutional Trust Company N.A. bought a new stake in DBV Technologies SA during the second quarter worth about $232,000. JPMorgan Chase & Co. boosted its stake in DBV Technologies SA by 6.6% in the second quarter. JPMorgan Chase & Co. now owns 254,492 shares of the company’s stock worth $8,301,000 after buying an additional 15,849 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in DBV Technologies SA by 12.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 11,100 shares of the company’s stock worth $360,000 after buying an additional 1,200 shares during the last quarter. Finally, Exane Asset Management bought a new stake in DBV Technologies SA during the second quarter worth about $4,407,000. Institutional investors own 47.92% of the company’s stock.
DBV Technologies SA Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA and related companies with MarketBeat.com's FREE daily email newsletter.